about
Glia maturation factor deficiency suppresses 1-methyl-4-phenylpyridinium-induced oxidative stress in astrocytesSuppression of glia maturation factor expression prevents 1-methyl-4-phenylpyridinium (MPP⁺)-induced loss of mesencephalic dopaminergic neuronsAbsence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonismAlternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice.ENDOPLASMIC RETICULUM STRESS IN SEPSIS.ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice.Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol.Glia maturation factor expression in entorhinal cortex of Alzheimer's disease brain.Cold-inducible RNA-binding protein (CIRP) causes sepsis-associated acute lung injury via induction of endoplasmic reticulum stress.Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome.Motor phenotypes and molecular networks associated with germline deficiency of Ciz1.Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats.Measurement of Elevated IL-37 Levels in Acute Ischemic Brain Injury: A Cross-sectional Pilot Study.DNA damage and neurodegenerative phenotypes in aged Ciz1 null mice.Catechin hydrate ameliorates redox imbalance and limits inflammatory response in focal cerebral ischemia.Ocimum sanctum attenuates oxidative damage and neurological deficits following focal cerebral ischemia/reperfusion injury in rats.Hesperidin ameliorates functional and histological outcome and reduces neuroinflammation in experimental stroke.Consequences of Cre-mediated deletion of Ciz1 exon 5 in miceDNA double-strand breaks: a potential therapeutic target for neurodegenerative diseases
P50
Q33911558-BCC5FAB7-C77F-488C-8625-A7EDC8A7A058Q34183725-DF85E35E-DDA5-483A-83E3-FC23E92982AAQ35587423-E1BFCB88-627F-419C-A2AF-DA42430B3214Q35911222-8B311CEE-ED94-4308-80C1-7F3F86DA45B5Q36074357-E2D136D0-E55A-4EF9-B886-F7DBA734C3C0Q36166160-E3383035-8434-482A-A889-1ACA951B6E20Q36481121-66B3B3BB-1B4E-4A92-8021-C69D73BADAB9Q36704078-BDD16143-1FBF-4561-A8F6-372CF14626C3Q37075794-05AC1250-E955-4773-8C16-F2904A86123BQ37609395-AF6EE38E-58C3-4800-A58B-4E662C47B803Q39150577-1E588A42-B36B-4AC9-BB19-79B89A00429CQ39779374-D40A062C-EECD-49CC-8D3E-03E86EB1510FQ44272311-F97F367F-20E0-4280-9CDF-493737F8D06DQ46851882-84497B77-6C31-4623-9F98-B4A32094F612Q47386934-1CE0686F-1248-41DB-8487-F61D927E5B14Q48524101-C3FCF14D-518A-4FDD-AAAF-EA0D15F578FAQ48692103-550E87F9-6585-4835-8E6C-4FF8276A4C7CQ48871746-2AB60307-EADD-43D2-AF01-194A5D8B62E2Q90883267-C880E270-115A-4221-88A1-4849D68EC9B4Q91212338-CACFC270-CFD8-4DC3-BE07-9EEDFE7AB984
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mohammad Moshahid Khan
@ast
Mohammad Moshahid Khan
@en
Mohammad Moshahid Khan
@es
Mohammad Moshahid Khan
@nl
type
label
Mohammad Moshahid Khan
@ast
Mohammad Moshahid Khan
@en
Mohammad Moshahid Khan
@es
Mohammad Moshahid Khan
@nl
prefLabel
Mohammad Moshahid Khan
@ast
Mohammad Moshahid Khan
@en
Mohammad Moshahid Khan
@es
Mohammad Moshahid Khan
@nl
P106
P31
P496
0000-0003-4679-294X